TITLE

LONG TERM PRESCRIBING OF PROTON PUMP INHIBITORS IN PRIMARY CARE--A CROSS SECTIONAL SURVEY

AUTHOR(S)
Raghunath, A. S.; Hungin, A. P. S.
PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA24
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents a cross sectional survey of long term prescribing of proton pump inhibitors (PPI) in primary care. PPIs constitute the single largest sector of primary care prescribing budget. £328 million WQS was spent on PPIs in year 2000 and most of this is related to long term prescribing in primary care. One previous study had shown that 0.45% of the population are on long term PPIs. This large cross sectional study has demonstrated a sixfold variation in long term prescribing rates of PPIs in primary care.
ACCESSION #
13218907

 

Related Articles

  • Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. Cahir, Caitriona; Fahey, Tom; Tilson, Lesley; Teljeur, Conor; Bennett, Kathleen // BMC Health Services Research;2012, Vol. 12 Issue 1, p408 

    Background: There are concerns that proton pump inhibitors (PPI) are being over prescribed in both primary and secondary care. This study aims to establish potential cost savings in a community drug scheme for a one year period according to published clinical and cost-effective guidelines for...

  • Rabeprazole: A Viewpoint by Noriaki Takeguchi. Takeguchi, N. // Drugs;Feb1998, Vol. 55 Issue 2, p268 

    Presents a viewpoint on the efficacy of rabeprazole against acid-related disorders. Mechanism of action of the medication; Characteristics as a proton pump inhibitor.

  • Rabeprazole: A Viewpoint by Simmy Bank. Bank, S. // Drugs;Feb1998, Vol. 55 Issue 2, p268 

    Presents a viewpoint on the efficacy of rabeprazole against acid-related disorders. Mechanism of action; Characteristics as a proton pump inhibitor; Results of clinical trials on the medication.

  • Clinical Pharmacology of Proton Pump Inhibitors: What the Practising Physician Needs to Know. Robinson, Malcolm; Horn, John // Drugs;2003, Vol. 63 Issue 24, p2739 

    Proton pump inhibitors (PPIs) [omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole] are widely utilised for the treatment of gastro-oesophageal reflux disease, as well as other acid-related disorders. All PPIs suppress gastric acid secretion by blocking the gastric acid pump,...

  • Review: Proton-pump inhibitor therapy reduces symptoms in nonulcer dyspepsia better than placebo.  // ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p74 

    This article presents a study, which reports that proton-pump inhibitor (PPI) therapy reduces symptoms in nonulcer dyspepsia (NUD) better than placebo. The study method consisted of randomized controlled trials that compared PPI therapy with placebo, receptor antagonists, prokinetic therapy,...

  • Proton Pump Inhibitors and the Risk of Colorectal Cancer. van Soest, Eva M.; van Rossum, Leo G.M.; Dieleman, Jeanne P.; van Oijen, Martijn G.H.; Siersema, Peter D.; Sturkenboom, Miriam C.J.M.; Kuipers, Ernst J. // American Journal of Gastroenterology;Apr2008, Vol. 103 Issue 4, p966 

    INTRODUCTION: Proton pump inhibitor (PPI) use is associated with increased serum gastrin levels and bacterial overgrowth, resulting in more toxic bile salt formation. Concern has risen that these factors may increase the risk of developing colorectal neoplasia. AIM: To investigate the...

  • Pharmacokinetics of Tenatoprazole, a Newly Synthesized Proton Pump Inhibitor, in Healthy Male Caucasian Volunteers. Domagala, Florence; Ficheux, Hervé; Houin, Georges; Barré, Jérôme // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Jan2006, Vol. 56 Issue 1, p33 

    The pharmacokinetics of tenatoprazole (CAS 113712-98-4), a newly synthesized proton pump inhibitor, and its metabolites TU-501 (sulfide form) and TU-502 (sulfone form) were investigated in an ascending-dose parallel-group study at the dose levels of 10, 20, 40, 80 and 120 mg. A total of 30...

  • Is double-dose PPI use warranted in upper GI symptoms?  // PharmacoEconomics & Outcomes News;8/9/2008, Issue 559, p10 

    The article discusses research being done on proton pump inhibitors (PPI). It references a study by L. E. Targownik et al, published in a June 2008 issue of "Digestive Diseases and Sciences." Canadian researchers found that initial prescription of double-dose PPI did not lead to a reduction in...

  • Intravenous Lansoprazole: A Viewpoint by Malcolm Robinson. Robinson, Malcolm // Drugs;2004, Vol. 64 Issue 18, p2090 

    Proton pump inhibitor (PPI) lansoprazole is now available in an intravenous (IV) formulation in North America. PPI work by inhibiting active proton pumps and are most effective when administered with meals. Hospitalized patients who received IV PPI are fasting and they may be expected to be...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics